Acrivon Therapeutics (ACRV) announced that Mansoor Raza Mirza, M.D., has been appointed Chief Medical Officer of the company, effective April 9. With the appointment of Dr. Mirza, the company’s current Chief Medical Officer, Jean-Marie Cuillerot, M.D., will depart the company on April 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
- Acrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
- Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
- Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
- Acrivon Therapeutics Reports 2024 Financial Results and Progress